It has recently been shown that mutations in KRAS exon 2 predict resistance to anti-EGFR treatment in metastatic CRC. As such prospective evaluation of KRAS mutation status is incorporated into routine clinical practice. Further, other mutations at hotspots in KRAS exons 3 or 4, or mutations at hotspots in NRAS exons 2,3 or 4 were found to confer similar resistance to this class of drugs. Consequently, evaluation of extended RAS mutation status is now routinely undertaken using a tumour tissue sample in order to determine the suitability for treatment with anti-EGFR antibodies.

Study Chair

Dr Daniel Cox
Austin Health, Melbourne

Download materials

Download the full abstract

Download the study schema

Study schema